Company Filing History:

9 out of 1,455

Sanofi

Bayer Aktiengesellschaft

patents

Years Active: 2003-2015

Loading Chart...

21 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9079906 - Triazolopyridazines as PAR1 inhibitors, production thereof, and use as medicaments (2015-07-14),

2. 8871798 - Tricyclic pyridyl-vinyl pyrroles as PAR1 inhibitors (2014-10-28),

3. 8853206 - Triazolium salts as PAR1 inhibitors, production thereof, and use as medicaments (2014-10-07),

4. 8791133 - Pyridylvinylpyrazoloquinolines as PAR1 inhibitors (2014-07-29),

5. 8598177 - Imidazopyridazines as PAR1 inhibitors, production thereof, and use as medicaments (2013-12-03),

6. 8580813 - Cyclic azaindole-3-carboxamides, their preparation and their use as pharmaceuticals (2013-11-12),

7. 8466169 - [object Object] (2013-06-18),

8. 8415336 - Cyclic (aza)indolizinecarboxamides, their preparation and their use as pharmaceuticals (2013-04-09),

9. 8263621 - Tartrate derivatives for use as coagulation factor IXa inhibitors (2012-09-11),

10. 8211885 - Cyclic indole-3-carboxamides, their preparation and their use as pharmaceuticals (2012-07-03),

11. 8198272 - Triazolium salts as PAR1 inhibitors, production thereof, and use as medicaments (2012-06-12),

12. 8153647 - Aryl- and heteroaryl-ethyl-acylguanidine derivatives, their preparation and their application in therapeutics (2012-04-10),

13. 8143242 - Malonamide derivatives with antithrombotic activity (2012-03-27),

14. 8097758 - Isoserine derivatives for use as coagulation factor IXa inhibitors (2012-01-17),

15. 8076336 - Triazolopyridazines as PAR1 inhibitors, production thereof, and use as medicaments (2011-12-13),

Title: Innovations and Contributions of Henning Steinhagen in Antithrombotic Research

Introduction

Henning Steinhagen, a prolific inventor based in Sulzbach, Germany, has made significant contributions to the field of medicinal chemistry. With a remarkable portfolio of 21 patents, he has been at the forefront of developing new therapeutic compounds, particularly those addressing antithrombotic activities.

Latest Patents

Among his latest innovations, Steinhagen has developed novel compounds that serve as PAR1 inhibitors. His patent entitled "Triazolopyridazines as PAR1 inhibitors, production thereof, and use as medicaments" presents compounds designed to inhibit protease-activated receptor 1 (PAR1). These compounds exhibit antithrombotic activity, marking an important development in the field. Another notable patent, "Tricyclic pyridyl-vinyl pyrroles as PAR1 inhibitors," also outlines compounds with significant antithrombotic properties. Both patents detail processes for synthesizing these compounds and their applications as pharmaceutical products.

Career Highlights

Steinhagen's career highlights include his tenure at prominent pharmaceutical companies such as Sanofi and Sanofi-Aventis. His work in these organizations has facilitated his groundbreaking research and development in the pharmaceutical industry, particularly in the creation of novel medicaments.

Collaborations

Throughout his career, Henning Steinhagen has collaborated with esteemed colleagues, including Uwe Heinelt and Matthias Herrmann. These partnerships have enhanced his research efforts and contributed to the successful development of his innovative compounds.

Conclusion

Henning Steinhagen's contributions to the field of antithrombotic research through his extensive patent portfolio are a testament to his inventive prowess. His innovative work in developing PAR1 inhibitors not only advances medical science but also holds the potential for significant therapeutic applications.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com